{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:07:56Z","timestamp":1761156476560,"version":"3.40.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bulcan.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T18:39:57Z","timestamp":1523299197000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["La chimioth\u00e9rapie n\u00e9oadjuvante associ\u00e9e \u00e0 la chimioradioth\u00e9rapie concomitante dans le traitement du cancer du nasopharynx\u00a0: exp\u00e9rience du Sud-Tunisien"],"prefix":"10.1016","volume":"105","author":[{"given":"Wafa","family":"Mnejja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-3943","authenticated-orcid":false,"given":"Nejla","family":"Fourati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racem","family":"Bouzguenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelmonem","family":"Ghorbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Frikha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wicem","family":"Siala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamel","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.02.004_bib0120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(97)07269-3","article-title":"Nasopharyngeal carcinoma","volume":"350","author":"Vokes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semradonc.2012.03.008","article-title":"Current management of nasopharyngeal cancer","volume":"22","author":"Lee","year":"2012","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0130","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherpy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","article-title":"Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival","volume":"21","author":"Lin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0140","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2002.08.149","article-title":"Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial","volume":"20","author":"Chan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0145","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/JCO.2004.10.074","article-title":"The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature","volume":"22","author":"Langendijk","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0150","first-page":"218","article-title":"Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis","volume":"43","author":"Yang","year":"2008","journal-title":"Zhonghua Erbi Yanhou Toujing Waike Zazhi"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753\u00a0patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0160","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/1471-2407-10-558","article-title":"The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials","volume":"10","author":"Zhang","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0165","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2004.07.702","article-title":"Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience","volume":"61","author":"Lee","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0170","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0360-3016(95)00218-N","article-title":"A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma","volume":"33","author":"Chan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0175","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.0.CO;2-T","article-title":"Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma","volume":"83","author":"Chua","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0360-3016(96)80007-1","article-title":"Preliminary results of trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression free survival","volume":"35","author":"Cvitkovic","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0190","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/annonc\/mdt146","article-title":"Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials","volume":"24","author":"OuYang","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7150\/jca.11814","article-title":"Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials","volume":"6","author":"Chen","year":"2015","journal-title":"J Cancer"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0200","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.oraloncology.2015.05.006","article-title":"Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma \u2013 a time-to-event meta-analysis","volume":"51","author":"Song","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0205","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0215","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","author":"Frikha","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0220","doi-asserted-by":"crossref","first-page":"16664","DOI":"10.1038\/srep16664","article-title":"Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy","volume":"5","author":"Du","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.oraloncology.2016.10.011","article-title":"Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemo-radiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma","volume":"62","author":"Ou","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bulcan.2018.02.004_bib0115","doi-asserted-by":"crossref","first-page":"42624","DOI":"10.1038\/srep42624","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis","volume":"7","author":"Lan","year":"2017","journal-title":"Sci Rep"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T11:53:16Z","timestamp":1534938796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118300778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0007455118300778"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La chimioth\u00e9rapie n\u00e9oadjuvante associ\u00e9e \u00e0 la chimioradioth\u00e9rapie concomitante dans le traitement du cancer du nasopharynx\u00a0: exp\u00e9rience du Sud-Tunisien","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}